Chembio and Lumira to Develop POC Tests in the ‘Heat’ of COVID-19 Outbreak
Chembio Diagnostics has enlisted LumiraDx to develop point-of-care tests for the detection of the coronavirus (COVID-19). Demand for COVID-19 diagnostics is at a fever-pitch in the US as there is a huge struggle to get the tests into the healthcare system.
Â
Gail Page, Chembio Diagnosticsâs interim president and CEO went in more detail about working with Waltham, MA-based LumiraDx during a call with investors. Page said the diagnostics developed in the collaboration would be used on both the LumiraDx and Chembio DPP platforms.
Â
âThis expands and strengthens our existing relationship with LumiraDx and further demonstrates our scientific expertise and the versatility of our DPP platform,â Page said, according to a Seeking Alpha transcript of the call. â[Through these] joint efforts we expect the new products to provide comprehensive solutions to the new demand surrounding the worldwide testing needs for COVID-19.â
Â
Page shed more light on the details of the agreement.
Â
âThere's a lot more in this agreement that again properly incentivizes and rewards both of us for getting the test to the market in a very expeditious manner,â Page said according to a Seeking Alpha transcript of the call. â⦠but also, again to point out that we're all very focused taking all the intel...
Source: MDDI - Category: Medical Devices Authors: Omar Ford Tags: Regulatory and Compliance Business Source Type: news
More News: Conferences | Coronavirus | COVID-19 | Emergency Medicine | Laboratory Medicine | Medical Devices | Outbreaks | SARS | Schools